Viewing Study NCT00357123


Ignite Creation Date: 2025-12-18 @ 8:20 AM
Ignite Modification Date: 2025-12-23 @ 10:22 PM
Study NCT ID: NCT00357123
Status: None
Last Update Posted: 2011-02-21 00:00:00
First Post: 2006-07-26 00:00:00
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: Effect of Rosuvastatin in Abdominal Sepsis
Sponsor: None
Organization:

Study Overview

Official Title: Use of Rosuvastatin in Integral Management of Abdominal Sepsis
Status: None
Status Verified Date: 2010-09
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The sepsis is often lethal, the mortality's ranks are identified among 25 to 70%, this depends on definition, severity and co-morbidities. The number of deaths by sepsis could be similar to myocardial infarct. Patients who get shock have 26-fold risk of death.

In preliminary studies have been observed, that patients with treatment with statin have minor incidence of severe sepsis. A retrospective study suggests the association between using statins and reduction of bacteriemia by Gram negatives and S. aureus.

There are many experimental studies which demonstrate the possible profit in sepsis. However there are no clinical prospective studies for determinate if statins are effective in management of sepsis. The investigators designed this study to demonstrate the utility of rosuvastatin in one kind of sepsis, abdominal sepsis.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: